Delapril/manidipine

Drug Profile

Delapril/manidipine

Alternative Names: Bimade; CHF 1521; Esprit (delapril/manidipine); Hipertil; Manidipine/delapril; Vivace

Latest Information Update: 23 Mar 2015

Price : $50

At a glance

  • Originator Takeda
  • Developer Chiesi
  • Class Antihypertensives; Dihydropyridines; Indans
  • Mechanism of Action ACE inhibitors; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 20 Oct 2003 A study has been added to the adverse events and Hypertension therapeutic trials sections
  • 09 Jan 2002 Registered for Hypertension in Italy (Unknown route)
  • 02 Sep 1999 Phase-III clinical trials for Hypertension in Italy (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top